Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians ...

Designation, together with a permanent HCPCS code effective October 1, 2026, supports patient access and reimbursement for PYLARIFY TruVu, Lantheus' PSMA PET imaging agentBEDFORD, Mass., Sept. 30, ...

Roughly 1 in 8 men receive a prostate cancer diagnosis at some stage in their lives, but only about 1 in 44 men will die of ...

Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians ...

Study advances development of Lantheus' investigational GRPR-targeted PET imaging program for prostate cancerBEDFORD, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- ("Lantheus" or the "Company") (NASDAQ: ...

People looking to stay healthy and tone up instead find themselves heading down a path of food restriction and guilt.

Researchers at The University of Texas MD Anderson Cancer Center have identified a previously unknown pathway that prostate ...

The first sub-study will support international research in the UK, US and South Africa, known as SAMBAI, aiming to understand factors that influence cancer outcomes in underserved populations of ...

Learn how prostate cancer is treated at each stage, from active surveillance and surgery to radiation, hormone therapy, and targeted drugs.

Must-Read Posts In GU Oncology This Week / bladder cancer, cancer, cancer care, Cancer research, cancer treatment, ...

Add Yahoo as a preferred source to see more of our stories on Google. Imagine there's a button inside your body that provides pleasure in the style of the early aughts "That Was Easy" button. As it ...